Submitted:
21 May 2023
Posted:
23 May 2023
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
2.1. Study design
2.2. Participants
2.3. Interventions
- The current practice of dispensary observation of patients receiving CR (basic/standard) care in both groups of study participants includes a mandatory amount of assistance as part of outpatient treatment at the patient’s place of residence, as prescribed by the orders of the Ministry of Health of the Republic of Kazakhstan, the clinical protocol: On approval of the rules for organizing the provision of medical care to people with chronic diseases, the frequency and timing of observation, the mandatory minimum and frequency of diagnostic studies. Order of the Minister of Health of the Republic of Kazakhstan dated October 23, 2020 No. RK HM-149 /2020 (registered in the Register of State Registration of Regulatory Legal Acts under No. 21513). Available from: https://adilet.zan.kz/rus/docs/V2000021513
- On approval of the Rules for provision of medical rehabilitation. The order of the Minister of Healthcare of the Republic of Kazakhstan dated October 7, 2020 No. KR HM- 116/2020 (registered in the Register of state registration of regulatory legal acts under No. 21381). Available from: https://adilet.zan.kz/rus/docs/V2000021381
- Clinical protocol for medical rehabilitation stage third "outpatient rehabilitation ii". profile "cardiology and cardiac surgery" (adults) Recommended by the Expert Council of the RSE on REM "Republican Center for Health Development" of the Ministry of Health and Social Development of the Republic of Kazakhstan dated December 12, 2014 Protocol No. 9. Available from: https://endovascular.kz/ru/rekomendatsii/klinicheskie-protokoly-mz-rk/tretij-etap-ambulatornaya-reabilitatsiya-ii-profil-kardiologiya-i-kardiokhirurgiya-vzroslye
2.4. Educational intervention
2.5. Collection of information
2.6. Statistical analysis
3. Results
4. Discussion
4.1. Goals of CR programs
4.2. Psychological component in outpatient CR
4.3. Strengths and limitations
4.4. Practical Significance
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Bennett, J.E.; Stevens, G.A.; Mathers, C.D.; Bonita, R.; Rehm, J.; Kruk, M.E.; Riley, L.M.; Dain, K.; Kengne, A.P.; Chalkidou, K.; et al. NCD Countdown 2030: worldwide trends in non-communicable disease mortality and progress towards Sustainable Development Goal target 3.4. Lancet 2018, 392, 1072–1088, doi:Doi 10.1016/S0140-6736(18)31992-5.
- Wells, A.; Reeves, D.; Heal, C.; Fisher, P.; Doherty, P.; Davies, L.; Heagerty, A.; Capobianco, L. Metacognitive therapy home-based self-help for anxiety and depression in cardiovascular disease patients in the UK: A single-blind randomised controlled trial. PLoS Med 2023, 20, e1004161. [CrossRef]
- Olsson, K.M.; Meltendorf, T.; Fuge, J.; Kamp, J.C.; Park, D.H.; Richter, M.J.; Gall, H.; Ghofrani, H.A.; Ferrari, P.; Schmiedel, R.; et al. Prevalence of Mental Disorders and Impact on Quality of Life in Patients With Pulmonary Arterial Hypertension. Front Psychiatry 2021, 12, 667602. [CrossRef]
- Aggarwal, M.; Ornish, D.; Josephson, R.; Brown, T.M.; Ostfeld, R.J.; Gordon, N.; Madan, S.; Allen, K.; Khetan, A.; Mahmoud, A.; et al. Closing Gaps in Lifestyle Adherence for Secondary Prevention of Coronary Heart Disease. Am J Cardiol 2021, 145, 1–11. [CrossRef]
- Zambrano, J.; Celano, C.M.; Januzzi, J.L.; Massey, C.N.; Chung, W.J.; Millstein, R.A.; Huffman, J.C. Psychiatric and Psychological Interventions for Depression in Patients With Heart Disease: A Scoping Review. J Am Heart Assoc 2020, 9, e018686. [CrossRef]
- Zheng, X.; Zheng, Y.; Ma, J.; Zhang, M.; Zhang, Y.; Liu, X.; Chen, L.; Yang, Q.; Sun, Y.; Wu, J.; et al. Effect of exercise-based cardiac rehabilitation on anxiety and depression in patients with myocardial infarction: A systematic review and meta-analysis. Heart Lung 2019, 48, 1–7. [CrossRef]
- Choo, C.C.; Chew, P.K.H.; Lai, S.M.; Soo, S.C.; Ho, C.S.; Ho, R.C.; Wong, R.C. Effect of Cardiac Rehabilitation on Quality of Life, Depression and Anxiety in Asian Patients. Int J Environ Res Public Health 2018, 15, 1095. [CrossRef]
- Carroll, D.L.; Malecki-Ketchell, A.; Astin, F. Non-pharmacological interventions to reduce psychological distress in patients undergoing diagnostic cardiac catheterization: a rapid review. Eur J Cardiovasc Nurs 2017, 16, 92–103. [CrossRef]
- Berg, L.J.; Arons, D.; Deng, J.; Green, A.L.; Taneja, M.; Wang, C.; Liu, S.S. Cardiac Coaches: A Student-Led Inpatient Cardiac Rehabilitation Program in the COVID-19 Era. Acad Med 2021, 96, e24. [CrossRef]
- Shi, W.; Ghisi, G.L.M.; Zhang, L.; Hyun, K.; Pakosh, M.; Gallagher, R. Systematic review, meta-analysis and meta-regression to determine the effects of patient education on health behaviour change in adults diagnosed with coronary heart disease. J Clin Nurs 2022. [CrossRef]
- Ertugrul, B.; Ozden, D. Physical Restraint Experiences of Family Caregivers of Patients With Stroke in Turkey: A Qualitative Study. Clin Nurs Res 2023, 32, 499–509. [CrossRef]
- Crocker, T.F.; Brown, L.; Lam, N.; Wray, F.; Knapp, P.; Forster, A. Information provision for stroke survivors and their carers. Cochrane Database of Systematic Reviews 2021. [CrossRef]
- Paterick, T.E.; Patel, N.; Tajik, A.J.; Chandrasekaran, K. Improving health outcomes through patient education and partnerships with patients. In Proceedings of the Baylor University Medical Center Proceedings, 2017; pp. 112–113.
- Timmers, T.; Janssen, L.; Kool, R.B.; Kremer, J.A. Educating Patients by Providing Timely Information Using Smartphone and Tablet Apps: Systematic Review. J Med Internet Res 2020, 22, e17342. [CrossRef]
- Menezes, P.; Guraya, S.Y.; Guraya, S.S. A Systematic Review of Educational Interventions and Their Impact on Empathy and Compassion of Undergraduate Medical Students. Frontiers in Medicine 2021, 8, 758377. [CrossRef]
- Meinema, J.G.; Buwalda, N.; van Etten-Jamaludin, F.S.; Visser, M.R.; van Dijk, N. Intervention descriptions in medical education: what can be improved? A systematic review and checklist. Academic Medicine 2019, 94, 281.
- Shal’nova, S.A.; Evstifeeva, S.E.; Deev, A.D.; Artamova, G.V.; Gatagonova, T.M.; Dupliakov, D.V.; Efanov, A.; Zhernakova Iu, V.; Konradi, A.O.; Libis, R.A.; et al. [The prevalence of anxiety and depression in different regions of the Russian Federation and its association with sociodemographic factors (according to the data of the ESSE-RF study)]. Ter Arkh 2014, 86, 53–60. [CrossRef]
- Santor, D.A.; Debrota, D.; Engelhardt, N.; Gelwicks, S. Optimizing the ability of the Hamilton Depression Rating Scale to discriminate across levels of severity and between antidepressants and placebos. Depress Anxiety 2008, 25, 774–786. [CrossRef]
- Wu, Y.; Levis, B.; Sun, Y.; He, C.; Krishnan, A.; Neupane, D.; Bhandari, P.M.; Negeri, Z.; Benedetti, A.; Thombs, B.D.; et al. Accuracy of the Hospital Anxiety and Depression Scale Depression subscale (HADS-D) to screen for major depression: systematic review and individual participant data meta-analysis. BMJ 2021, 373, n972. [CrossRef]
- Davies, T.; Garman, E.C.; Lund, C.; Schneider, M. Adaptation and validation of a structured version of the Hamilton Depression Rating Scale for use by non-clinicians in South Africa (AFFIRM-HDRS). J Eval Clin Pract 2020, 26, 1425–1435. [CrossRef]
- Hieronymus, F.; Jauhar, S.; Østergaard, S.D.; Young, A.H. One (effect) size does not fit at all: interpreting clinical significance and effect sizes in depression treatment trials. Journal of Psychopharmacology 2020, 34, 1074–1078.
- Lemay, K.R.; Tulloch, H.E.; Pipe, A.L.; Reed, J.L. Establishing the Minimal Clinically Important Difference for the Hospital Anxiety and Depression Scale in Patients With Cardiovascular Disease. J Cardiopulm Rehabil Prev 2019, 39, E6–E11. [CrossRef]
- Zhamankulova, D.G.; Zhamaliyeva, L.M.; Kurmanalina, G.L.; Tanbetova, Z.; Grjibovski, A.M. Public Health Rehabilition after Acute Myocardial Infarction: a Randomized Controlled Study. Human Ecology 2021, 8, 57–64.
- Hushcha, P.; Jafri, S.H.; Malak, M.M.; Parpos, F.; Dorbala, P.; Bousquet, G.; Lutfy, C.; Sonis, L.; Cabral, L.; Mellett, L.; et al. Weight Loss and Its Predictors During Participation in Cardiac Rehabilitation. Am J Cardiol 2022, 178, 18–25. [CrossRef]
- Sestayo Fernandez, M.; Alonso Vazquez, M.; Gonzalez Maestro, A.; Gonzalez Salvado, V.; Diaz Balboa, E.; Neiro Rey, M.; Gonzalez Juanatey, J.; Pena Gil, C. Changes in smoking status after a cardiac rehabilitation program in Spain: description of a smoker’s profile. European Heart Journal 2022, 43, ehac544. 2382.
- Sadeghi, M.; Shabib, G.; Masoumi, G.; Amerizadeh, A.; Shahabi, J.; Heidari, R.; Roohafza, H. A Systematic Review and Meta-analysis on the Prevalence of Smoking Cessation in Cardiovascular Patients After Participating in Cardiac Rehabilitation. Curr Probl Cardiol 2021, 46, 100719. [CrossRef]
- Wu, G.; Hu, Y.; Ding, K.; Li, X.; Li, J.; Shang, Z. The Effect of Cardiac Rehabilitation on Lipid Levels in Patients with Coronary Heart Disease. A Systematic Review and Meta-Analysis. Glob Heart 2022, 17, 83. [CrossRef]
- Akowuah, E.; Mathias, A.; Bardgett, M.; Harrison, S.; Kasim, A.S.; Loughran, K.; Ogundimu, E.; Trevis, J.; Wagnild, J.; Witharana, P. Prehabilitation in elective patients undergoing cardiac surgery: a randomised control trial (THE PrEPS TRIAL)–a study protocol. BMJ open 2023, 13, e065992.
- Gao, Y.; Yue, L.; Miao, Z.; Wang, F.; Wang, S.; Luan, B.; Hao, W. The Effect and Possible Mechanism of Cardiac Rehabilitation in Partial Revascularization Performed on Multiple Coronary Artery Lesions. Clin Interv Aging 2023, 18, 235–248. [CrossRef]
- Rush, A.J.; South, C.; Jain, S.; Agha, R.; Zhang, M.; Shrestha, S.; Khan, Z.; Hassan, M.; Trivedi, M.H. Clinically Significant Changes in the 17- and 6-Item Hamilton Rating Scales for Depression: A STAR*D Report. Neuropsychiatr Dis Treat 2021, 17, 2333–2345. [CrossRef]
- Hengartner, M.P.; Ploderl, M. Estimates of the minimal important difference to evaluate the clinical significance of antidepressants in the acute treatment of moderate-to-severe depression. BMJ Evid Based Med 2022, 27, 69–73. [CrossRef]
- Kirsch, I.; Deacon, B.J.; Huedo-Medina, T.B.; Scoboria, A.; Moore, T.J.; Johnson, B.T. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008, 5, e45. [CrossRef]
- Zimmerman, M.; Chelminski, I.; Posternak, M. A review of studies of the Hamilton depression rating scale in healthy controls: implications for the definition of remission in treatment studies of depression. J Nerv Ment Dis 2004, 192, 595–601. [CrossRef]
- Cuijpers, P.; Quero, S.; Dowrick, C.; Arroll, B. Psychological Treatment of Depression in Primary Care: Recent Developments. Curr Psychiatry Rep 2019, 21, 129. [CrossRef]
- Tully, P.J.; Ang, S.Y.; Lee, E.J.; Bendig, E.; Bauereiss, N.; Bengel, J.; Baumeister, H. Psychological and pharmacological interventions for depression in patients with coronary artery disease. Cochrane Database Syst Rev 2021, 12, CD008012. [CrossRef]
- Taylor, R.S.; Dalal, H.M.; McDonagh, S.T.J. The role of cardiac rehabilitation in improving cardiovascular outcomes. Nat Rev Cardiol 2022, 19, 180–194. [CrossRef]
- Wells, A.; Reeves, D.; Capobianco, L.; Heal, C.; Davies, L.; Heagerty, A.; Doherty, P.; Fisher, P. Improving the Effectiveness of Psychological Interventions for Depression and Anxiety in Cardiac Rehabilitation: PATHWAY-A Single-Blind, Parallel, Randomized, Controlled Trial of Group Metacognitive Therapy. Circulation 2021, 144, 23–33. [CrossRef]
- Rathore, S.; Kumar, B.; Tehrani, S.; Khanra, D.; Duggal, B.; Chandra Pant, D. Cardiac rehabilitation: Appraisal of current evidence and utility of technology aided home-based cardiac rehabilitation. Indian Heart J 2020, 72, 491–499. [CrossRef]
- Thomas, R.J.; Beatty, A.L.; Beckie, T.M.; Brewer, L.C.; Brown, T.M.; Forman, D.E.; Franklin, B.A.; Keteyian, S.J.; Kitzman, D.W.; Regensteiner, J.G. Home-based cardiac rehabilitation: a scientific statement from the American Association of Cardiovascular and Pulmonary Rehabilitation, the American Heart Association, and the American College of Cardiology. Circulation 2019, 140, e69–e89.
- Ruivo, J.; Moholdt, T.; Abreu, A. Overview of Cardiac Rehabilitation (OCRE) Following Post-Acute Myocardial Infarction in European Society of Cardiology (ESC) Member Countries. Eur J Prev Cardiol 2023, zwad024. [CrossRef]
- Ayasrah, S.M.; Ahmad, M.M. Educational Video Intervention Effects on Periprocedural Anxiety Levels Among Cardiac Catheterization Patients: A Randomized Clinical Trial. Research and Theory for Nursing Practice 2016, 30, 70–84, doi:Doi 10.1891/1541-6577.30.1.70.
- Sharif, F.; Shoul, A.; Janati, M.; Kojuri, J.; Zare, N. The effect of cardiac rehabilitation on anxiety and depression in patients undergoing cardiac bypass graft surgery in Iran. BMC Cardiovasc Disord 2012, 12, 40. [CrossRef]

| Indices | Experimental group (n=76) | Control group (n=69) | P-value |
|---|---|---|---|
| Age, years (range) | 58 (52-68) | 59 (54.5-69) | 0.24 |
| SBP, mmHg (range) | 140 (130-150) | 130 (120-150) | 0.37 |
| DBP, mmHg (range) | 85 (80-90) | 80 (80-90) | 0.40 |
| Heart rate, bpm (range) | 75 (68-85) | 78 (70-80) | 0.44 |
| Cholesterol, mmol/L (range) | 5.6 (4.6-6.5) | 5.1 (4.2-6.5) | 0.15 |
| Triglycerides, mmol/L (range) | 1.2 (0.9-1.8) | 1.2 (0.9-1.8) | 0.82 |
| HDL, mmol/L (range) | 1.1 (0.9-1.3) | 1.2 (1.1-1.2) | 0.79 |
| LDL, mmol/L (range) | 3.5 (2.9-4.1) | 3.2 (2.5-4.2) | 0.44 |
| Glucose, mmol/L (range) | 6.7 (5.5-8.9) | 6.5 (5.2-7.9) | 0.15 |
| Creatinine, µmol/L (range) | 73 (66-89) | 79 (67.6-92.9) | 0.37 |
| Smoked, n (%) | 43 (56.6%) | 29 (42.0%) | 0.08 |
| Hypertension Grade 3, n (%) | 44 (57.9%) | 44 (63.8%) | 0.82 |
| Recurrent MI, n (%) | 12 (15.8%) | 17 (24.6%) | 0.18 |
| Stroke / TIA, n (%) | 7 (9.2%) | 8 (11.6%) | 0.57 |
| Diabetes mellitus, n (%) | 18 (23.7%) | 13 (18.8%) | 0.47 |
| Ejection fraction by echocardiography, n (%) | 50 (46-54) | 50 (45-53) | 0.50 |
| 6-minute walk test, n (%) | 365 (335-400) | 370 (330-440) | 0.62 |
| Gender | 0.12 | ||
| Male, n (%) | 58 (73.42%) | 61 (83.56%) | |
| Female, n (%) | 21 (26.58%) | 12 (16.44%) | |
| Place of residence | 0.44 | ||
| City, n (%) | 47 (59.49%) | 42 (57.53%) | |
| Rural area, n (%) | 19 (24.05%) | 23 (31.51%) | |
| Suburb, n (%) | 13 (16.46%) | 8 (10.96%) | |
| Marital status | 0.50 | ||
| Married, n (%) | 61 (77.22%) | 60 (82.19%) | |
| Divorced/Widower, n (%) | 16 (20.25%) | 10 (13.70%) | |
| Single, n (%) | 2 (2.53%) | 3 (4.11%) | |
| Education | 0.57 | ||
| Secondary, n (%) | 36 (45.57%) | 37 (51.39%) | |
| Vocational, n (%) | 22 (27.85%) | 21 (29.17%) | |
| Higher, n (%) | 21 (26.58%) | 14 (19.44%) | |
| Employment | 0.70 | ||
| Unemployed, n (%) | 34 (43.04%) | 34 (46.58%) | |
| Manual labor, n (%) | 31 (39.24%) | 24 (32.88%) | |
| Mental labor, n (%) | 14 (17.72%) | 15 (20.55%) | |
| HADS, anxiety, n (%) | 14 (18.42%) | 13 (18.84%) | 0.98 |
| Subclinical anxiety, n (%) | 9 (11.84%) | 8 (11.59%) | |
| Clinical anxiety, n (%) | 5 (6.58%) | 5 (7.25%) | |
| HADS, depression, n (%) | 12 (15.78%) | 10 (14.48%) | 0.97 |
| Subclinical depression, n (%) | 6 (7.89%) | 5 (7.24%) | |
| Clinically significant depression, n (%) | 6 (7.89%) | 5 (7.24%) | |
| Hamilton, depression, n (%) | 11 (14.47%) | 10 (14.49%) | 0.66 |
| Mild depressive disorder, n (%) | 5 (6.58%) | 5 (7.25%) | |
| Moderate depressive disorder, n (%) | 3 (3.95%) | 1 (1.45%) | |
| Severe depressive disorder, n (%) | 3 (3.95%) | 3 (4.35%) |
| Indices | Experimental (n=76) |
Control (n=69) |
P-value |
|---|---|---|---|
| BMI, kg/m2 | 27.1±4.8 | 28.3±3.8 | 0.00 |
| WC, sm | 97.2±13.1 | 102.2±12.2 | 0.01 |
| Cigarettes smoked per day, n | 1.9±4.2 | 6.2±8.9 | 0.00 |
| Systolic blood pressure, mmHg | 119.0±8.3 | 132.2±15.7 | 0.00 |
| Diastolic blood pressure, mmHg | 75.9±5.9 | 82.2±8.6 | 0.00 |
| Heart rate, bpm | 63.1±3.4 | 68.6±7.4 | 0.00 |
| Cholesterol, mmol/L | 4.1±0.8 | 4.9±1.2 | 0.00 |
| Triglycerides, mmol/L | 1.4±0.5 | 1.5±0.7 | 0.10 |
| HDL, mmol/L | 1.2±0.2 | 1.0±0.2 | 0.00 |
| LDL, mmol/L | 2.5±0.8 | 3.1±0.9 | 0.00 |
| Ejection fraction by echocardiography, % | 53.6±6.5 | 49.7±6.9 | 0.00 |
| 6-minute walk test, m | 442.6±71.8 | 372.2±101.4 | 0.00 |
| Death, n (%) | 3.0±3.8% | 4.0±5.4% | 0.62 |
| Recurrent MI, n (%) | 3.0±3.80% | 8.0±10.9% | 0.08 |
| Stroke / TIA, n (%) | 1.0±1.2% | 4.0±5.4% | 0.14 |
| Hospitalization, n (%) | 2.0±2.5% | 10.0±13.7% | 0.01 |
| Indices | Intervention group | Control group | P-value | Effect size (95%CI) |
|---|---|---|---|---|
| Body mass index, kg/m2 | -1.1±1.0 | 0.4±1.1 | <0.001 | -1.49 (96%CI -1.8; -1.12) |
| Waist circumference, cm | -3.4±2.4 | 1.8±2.7 | <0.001 | -2.08 (96%CI -2.5; -1.7) |
| Number of cigarettes a day, n | -10.6±11.2 | -2.6±7.2 | <0.001 | -0.8 (-1.18; -0.5) |
| Systolic blood pressure, mmHg | -18.7±18.4 | -4.9±25.5* p=0.11 |
<0.001 | -0.63 (96%CI -0.96; -0.3) |
| Diastolic blood pressure, mmHg | -8.16±9.4 | -1.3±12.4* p=0.39 |
<0.001 | -0.63 (96%CI -0.96; -0.3) |
| Heart rate, bpm | -12.9±11.9 | -8.2±11.2 | 0.01 | -0.4 (95%CI -0.7; -0.07) |
| Cholesterol, mmol/L | -1.57±1.2 | -0.39±1.2 | <0.001 | -0.98 (95%CI -1.3; -0.6) |
| Triglycerides, mmol/L | -0.08±0.7* p=0.38 |
0.13±0.7* p=0.16 |
0.10 | -0.3 (95%CI -0.6; 0.03) |
| HDL, mmol/L | 0.08±0.3 | -0.05±0.2* p=0.15 |
0.006 | 0.46 (95%CI 0.13; 0.8) |
| LDL, mmol/L | -0.9±1.1 | -0.2±0.9* p=0.07 |
<0.001 | -0.7 (95%CI -1.02; -0.36) |
| Ejection fraction by echocardiography, % | 4.2±4.9 | 0.7±4.6* p=0.19 |
<0.001 | 0.72 (95%CI 0.39; 1.06) |
| 6-minute walk test, m | 88.1±28.9 | 34.8±28.0 | <0.001 | 1.9 (95%CI 1.5; 2.3) |
| Characteristics | Experimental group, n=76 | P-value1 | Control group, n=69 | P-value1 | Experimental group changes | Control group changes | P-value2 | ||
|---|---|---|---|---|---|---|---|---|---|
| Before | After | Before | After | ||||||
| HADS anxiety | 3.9±3.2 | 1.9±1.5 | 0.0002 | 4.5±3.4 | 3.0±1.8 | <0.001 | -2.0 | -1.5 | 0.24 |
| HADS depression | 3.0±3.7 | 1.1±1.7 | <0.0001 | 3.8±3.9 | 2.6±2.9 | <0.001 | -1.9 | -1.2 | 0.21 |
| HDRS depression | 4.2±4.7 | 1.5±1.7 | 0.008 | 4.5±5.3 | 3.1±4.3 | <0.001 | -2.7 | -1.4 | 0.23 |
| Characteristics | Experimental group | Control group | P-value 2 | |||||
| Before, Positive outcome | Before, Negative outcome | P-value 1 | Before, Positive outcome | Before, Negative outcome | P-value 1 | |||
| HADS anxiety | <0.001 | 0.008 | 0.19 | |||||
| After, Negative outcome | 13 | 62 | 9 | 56 | ||||
| After, Positive outcome | 1 | 0 | 4 | 0 | ||||
| HADS depression | 0.002 | 0.04 | 0.07 | |||||
| After, Negative outcome | 12 | 64 | 8 | 58 | ||||
| After, Positive outcome | 0 | 0 | 2 | 1 | ||||
| HDRS depression | 0.008 | 0.68 | 0.06 | |||||
| After, Negative outcome | 9 | 65 | 4 | 57 | ||||
| After, Positive outcome | 2 | 0 | 6 | 2 | ||||
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).